The second stage of clinical trials of a drug for the treatment of systemic lupus erythematosus has begun in China
Chinese scientists have begun the second phase of clinical trials of the drug for the treatment of an autoimmune disease – systemic lupus erythematous.
The new patent-protected drug SM934, which is a water-soluble artemisinin derivative, was developed by researchers at the Shanghai Institute of Pharmacology at the Academy of Sciences of China ANC.
The first stage of clinical trials of a new drug has already been completed, and the second stage began in one of the Shanghai hospitals.
Systemic lupus erythematous, one of the most common types of lupus erythematous, is an autoimmune disease in which the human immune system mistakenly attacks healthy tissues of the body, causing damage to the joints, skin, kidneys, blood cells, brain, heart and lungs.
One of the hallmarks of lupus is a rash on the face, resembling butterfly wings in outline.
In China, nearly one million people are reported to have lupus erythematous.
Since the causes of the origin and development of the disease remain unclear, the development of new drugs for this disease causes difficulties.
According to the ANC, the drug SM934 is an oral drug with a low dosage and a pronounced effect. It can modulate autoimmune reactions and restore the body’s immune balance.